Co-Authors
This is a "connection" page, showing publications co-authored by William Petty and Jimmy Ruiz.
Connection Strength
1.000
-
Ruiz J, Petty WJ. Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer? Ann Transl Med. 2015 Mar; 3(3):31.
Score: 0.572
-
Ruiz J, Miller AA, Tooze JA, Crane S, Petty WJ, Gajra A, Klepin HD. Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. J Geriatr Oncol. 2019 01; 10(1):48-54.
Score: 0.180
-
Lycan TW, Pardee TS, Petty WJ, Bonomi M, Alistar A, Lamar ZS, Isom S, Chan MD, Miller AA, Ruiz J. A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PLoS One. 2016; 11(10):e0164244.
Score: 0.160
-
Bonomi M, Ahmed T, Addo S, Kooshki M, Palmieri D, Levine BJ, Ruiz J, Grant S, Petty WJ, Triozzi PL. Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis. Oncol Lett. 2019 Jan; 17(1):1349-1356.
Score: 0.046
-
Shenker RF, McTyre ER, Ruiz J, Weaver KE, Cramer C, Alphonse-Sullivan NK, Farris M, Petty WJ, Bonomi MR, Watabe K, Laxton AW, Tatter SB, Warren GW, Chan MD. The Effects of smoking status and smoking history on patients with brain metastases from lung cancer. Cancer Med. 2017 May; 6(5):944-952.
Score: 0.041